ClinicalTrials.gg
Active, not recruitingNCT06099548ELEVATE IUpdated May 30, 2025

Magenta Elevate™ First-in-Human Clinical Study in High-Risk PCI Patients

An interventional study of The Elevate™ System in High-Risk Percutaneous Coronary Intervention, sponsored by Magenta Medical Ltd.. Active, not recruiting at 2 sites in Georgia. Open to participants aged 40 Years to 83 Years. Per ClinicalTrials.gov, last updated 2025-05-30.

Sponsored by Magenta Medical Ltd. · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2026, 5 months ago, but the record still lists the study as active, not recruiting.
  • Registered 2 years 10 months after the study started (first participant enrolled Dec 2020, registered Oct 2023).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
40 Years to 83 Years
Sex
All
01

Study summary

The Elevate™ First-In-Human (FIH) study is designed to evaluate the initial safety and device functionality of the Elevate™ percutaneous Left Ventricular Assist Device (pLVAD) System in patients undergoing non-emergent, high-risk percutaneous coronary interventions.

Read the detailed description

The Elevate™ System FIH study is planned as a prospective, single-arm, interventional study of up to 20 patients.

The Magenta Elevate™ is a temporary (≤ 6 hours) ventricular support device indicated for use during high-risk percutaneous coronary interventions (HR-PCI) performed electively or urgently in hemodynamically stable patients, with severe coronary artery disease.

The Magenta Elevate™ Pump is a catheter-mounted, self-expanding and retrievable pump, designed to unload the left ventricle by actively transporting blood from the left ventricle into the ascending aorta.

02

Conditions studied

  • High-Risk Percutaneous Coronary Intervention

Keywords

  • HR-PCI
  • High-risk percutaneous coronary intervention
  • Mechanical Circulatory Support
  • Left ventricular unloading
  • HRPCI
  • Temporary MCS
03

In context

Lead sponsor

Magenta Medical Ltd. is the lead sponsor of 5 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years to 83 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Non-emergent, percutaneous coronary intervention is planned in at least one stenotic lesion of a native coronary artery or bypass graft (de novo or restenosis)
  2. of ≤ 45% and at least one of the following:

    1. Intervention on an unprotected left main coronary artery
    2. Intervention on a last patent coronary conduit
    3. Three-vessel disease (in case of left coronary artery dominance, the combination of a Left Anterior Descending Artery (LAD) lesion and a proximal Left Circumflex Artery (LCX) lesion qualifies as three-vessel disease)
  3. Femoral artery diameter compatible with the use of Elevate™
  4. Subject signed

Exclusion criteria

Exclusion Criteria:

  1. Subject age \< 40 or ≥ 83 years
  2. Cardiogenic shock
  3. Left ventricular mural thrombus
  4. Presence of a mechanical aortic valve or a heart-constrictive device
  5. Aortic stenosis
  6. Moderate or severe aortic regurgitation (≥ 2+ by Transthoracic Echocardiography)
  7. Severe peripheral vascular disease
  8. Aortic pathology, such as aortic aneurysms, extreme tortuosity or calcifications that could pose an undue additional risk to the placement of a pLVAD device
  9. Chronic renal dysfunction (serum creatinine ≥ 3.5 mg/dL)
  10. Uncorrectable abnormal coagulation parameters (defined as count ≤ 75,000 or ≥ 2.0 or fibrinogen ≤ 1.5 g/L)
  11. Active systemic infection
  12. Stroke or within 3 months of enrollment
  13. Female subjects who are pregnant or breast-feeding
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    HR-PCI patients

    Patients undergoing non-emergent, high-risk percutaneous coronary interventions

    Device: The Elevate™ System

Interventions

  • DeviceThe Elevate™ System

    The Magenta Elevate™ is a temporary (≤ 6 hours) ventricular support device indicated for use during high-risk percutaneous coronary interventions (HR-PCI) performed electively or urgently in hemodynamically stable patients, with severe coronary artery disease.

06

What researchers measure

Primary outcomes

  1. Device Performance

    Rate of procedural hypotension

    Time frame: Through the end of the procedure

  2. Device Safety

    Rate of Major Device-Related Adverse Events

    Time frame: Through the end of the procedure

07

Study locations

2 sites
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2020 (actual). Primary completion is estimated for Jun 2026, 65 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 18, 2023
First posted
Oct 25, 2023
StartActual
Dec 17, 2020
Primary completionEst.
Jun 1, 2026
CompletionEst.
Jun 1, 2026
Last update
May 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06099548
Lead sponsor
Magenta Medical Ltd.
Responsible party
Sponsor
First posted
Oct 25, 2023
Start date
Dec 17, 2020
Primary completion
Jun 1, 2026 (estimated)
Completion
Jun 1, 2026 (estimated)
Last update
May 30, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion